Sipagladenant (KW-6356) is an oral A2A adenosine receptor inverse agonist, investigated for cognitive and movement disorders like Parkinson’s disease and frontal lobe dysfunction, showing promise in animal models for improving cognition and gait, but its development by Kyowa Kirin was discontinued despite early positive signs. It works by blocking adenosine A2A receptors, potentially increasing dopamine function, and is used in research settings for studying neurological conditions. The directory classifies it as a discontinued API with a synthetic source/manufacturing origin. Other names for this substance include KW-6356. Its PubChem CID is 23144148.
Sipagladenant
| CAS No | 858979-50-7 |
|---|---|
| Molecular Formula | C20H19N3O4S |
| Molecular Weight | 397.4 g/mol |
| Synonyms | N-[4-(furan-2-yl)-5-(oxane-4-carbonyl)-1,3-thiazol-2-yl]-6-methylpyridine-3-carboxamide |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Sipagladenant (KW-6356) is an oral A2A adenosine receptor inverse agonist, investigated for cognitive and movement disorders like Parkinson's disease and frontal lobe dysfunction, showing promise in animal models for improving cognition and gait, but its development by Kyowa Kirin was discontinued despite early positive signs.
The listed CAS number is 858979-50-7.
The listed molecular formula is C20H19N3O4S.
The listed molecular weight is 397.4 g/mol.
N-[4-(furan-2-yl)-5-(oxane-4-carbonyl)-1,3-thiazol-2-yl]-6-methylpyridine-3-carboxamide.
The source lists KW-6356.